EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aroa Biosurgery's enterprise value is A$151.07 Mil.
Aroa Biosurgery's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was A$-2.89 Mil. Therefore, Aroa Biosurgery's EV-to-EBITDA for today is -52.36.
The historical rank and industry rank for Aroa Biosurgery's EV-to-EBITDA or its related term are showing as below:
ASX:ARX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.62 Med: -22.91 Max: 102.53
Current: -52.37
During the past 4 years, the highest EV-to-EBITDA of Aroa Biosurgery was 102.53. The lowest was -91.62. And the median was -22.91.
ASX:ARX's EV-to-EBITDA is ranked worse than 100% of 483
companies
in the Medical Devices & Instruments industry
Industry Median: 16.47
vs ASX:ARX: -52.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Aroa Biosurgery EV-to-EBITDA Historical Data
The historical data trend for Aroa Biosurgery's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aroa Biosurgery's EV-to-EBITDA
For the Medical Devices subindustry, Aroa Biosurgery's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's EV-to-EBITDA falls into.
Aroa Biosurgery's current Enterprise Value is A$151.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was A$-2.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aroa Biosurgery's PE Ratio for today is calculated as:
Aroa Biosurgery's share price for today is A$0.515.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was A$-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Aroa Biosurgery's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:ARX has been successfully added to your